Cita APA (7a ed.)
Ding, L., Nuersulitan, R., Wang, J., Chen, H., & Zhuo, M. (2026). Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology, 33(5), 258-268.
Cita Chicago Style (17a ed.)
Ding, Lu, Reyizha Nuersulitan, Jingjing Wang, Hanxiao Chen, y Minglei Zhuo. "Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression." Current Oncology 33, no. 5 (2026): 258-268.
Cita MLA (9a ed.)
Ding, Lu, et al. "Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression." Current Oncology, vol. 33, no. 5, 2026, pp. 258-268.
Precaución: Estas citas no son 100% exactas.